ArticleDiscover oncology2026
Machine learning-based identification of extracellular matrix-related prognostic subtypes in SHH-activated medulloblastoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMedulloblastoma (MB) is the most common malignant pediatric brain tumor, with the Sonic Hedgehog (SHH) subgroup exhibiting heterogeneous clinical outcomes. The extracellular matrix (ECM) critically modulates tumor behavior, yet its contribution to SHH-activated MB heterogeneity remains poorly defined.
methodsWe integrated bulk microarray expression profiles from GSE85217 and single-cell RNA-sequencing data (GSE155446) from SHH-activated MB. ECM-related gene sets were retrieved from MsigDB. Non-negative matrix factorization (NMF) was applied to microarray data to delineate ECM subtypes, followed by weighted gene co-expression network analysis (WGCNA) and differential expression analysis to identify core genes. A prognostic model was constructed using 101 machine-learning algorithm combinations. Single-cell data were processed with Seurat and Harmony, cell-type annotations were transferred via the Scissor algorithm, and cell–cell communication was inferred with CellChat.
resultsTwo distinct ECM-associated subtypes (C1 and C2) were identified within SHH-activated MB. C2 displayed a poor prognosis (log-rank P = 0.00015. The top 50 ranked by the MCC algorithm were used to build a Ridge-based prognostic signature that independently predicted overall survival (P < 0.0001). Single-cell mapping showed that the adverse C2 signature was primarily harbored by complement-activated myeloid cells. These cells engaged in strong MHC-II-mediated interactions with dendritic-like and M2-like myeloid cells, implicating myeloid-driven ECM remodeling in SHH-activated MB progression.
conclusionECM heterogeneity defines clinically relevant SHH-activated MB subtypes. A myeloid-centric, complement-activated microenvironment underpins the aggressive C2 subtype, offering tractable therapeutic targets to overcome current treatment limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.